Oklahoma’s medical cannabis industry is facing renewed scrutiny as concerns over varying laboratory findings fuel debate about product safety and the effectiveness of current oversight.
For Oklahoma patient Summer Parker, those concerns became deeply personal. She recalled experiencing severe episodes after smoking pre-rolls from Graves Farm Organics. According to Parker, she struggled to think clearly, had difficulty speaking, collapsed, and eventually required emergency medical assistance.
At first, she did not suspect the cannabis product. However, after similar incidents repeatedly followed the use of the same brand, she and her spouse, Charles Hrabina, decided to have several products independently analyzed.
Their lawsuit against the business alleges that testing revealed multiple pesticide failures, one microbial contamination issue, and a lower THC level than the manufacturer advertised.
The company and its founder, Michael Graves, deny any connection between the products and Parker’s medical episodes. Attorney Felina Rivera, representing the company, rejected claims that the products were defective but argued that Oklahoma’s marijuana testing framework suffers from major inconsistencies.
Rivera said identical samples submitted to several licensed laboratories can produce very different outcomes, a criticism echoed by others throughout the cannabis industry. The disagreement has intensified questions about whether patients can rely on the certificates of analysis that accompany legal marijuana products.
State law requires every medical cannabis product sold in Oklahoma to undergo testing before reaching dispensaries. Licensed laboratories examine samples for contaminants, including pesticides, heavy metals, microbes, mycotoxins, and residual solvents, while also measuring cannabinoid potency and terpene content.
Each approved batch receives a certificate of analysis documenting test results and confirming whether it met state requirements. Products that fail safety requirements cannot legally enter the marketplace.
Laboratories must be accredited, participate in proficiency testing, and follow standards established by the Oklahoma Medical Marijuana Authority (OMMA). They are also required to maintain safeguards intended to prevent financial interests from influencing laboratory findings.
Critics say that even with those protections, the pressure to compete makes producers want to find labs that are more likely to give them better results. Since THC percentages strongly influence purchasing decisions, even modest differences in reported potency can affect both pricing and sales.
OMMA acknowledges that lab shopping exists nationwide and says stronger oversight is essential. Since Oklahoma’s medical cannabis program launched, regulators have taken enforcement action against 29 laboratories. Some facilities have also been required to correct deficiencies after failing proficiency evaluations.
A 2023 law authorized OMMA to establish its own quality assurance laboratory to verify testing accuracy. Although the facility is still completing accreditation for several testing categories, officials say it already performs limited analyses for potency and pesticides. Once fully operational, it will compare identical samples across laboratories, conduct independent testing during investigations, and monitor overall laboratory performance.
Parker has since become an advocate for stronger oversight, co-founding Patients for Safe Access of Oklahoma. She said independent testing of roughly 40 products over two years revealed concerns extending beyond a single producer, including compounds not covered by Oklahoma’s required screening panel.
Outside Oklahoma’s regulated medical cannabis market, concerns grow even larger. Hemp-derived products containing intoxicating THC variants are sold through retailers that are not subject to the same testing standards, inspections, or consumer protections, leaving many experts warning that buyers face even greater uncertainty.
The entire marijuana industry, including established companies like SNDL Inc. (NASDAQ: SNDL), would want the issues linked to product testing addressed in different legal markets so that legally sourced products don’t trigger any doubts in the minds of consumers who should naturally trust the product labels attached to these items.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN